Pharmacotherapy of acute alcoholic hepatitis in clinical practice

World Journal of Gastroenterology

Volumn 20, Issue 9, 2014, Pages 2159-2167

  Abenavoli, Ludovico ^a   Milic, Natasa ^b   Rouabhia, Samir ^c   Addolorato, Giovanni ^d  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b UNIVERSITY OF NOVI SAD   (Serbia)

^c University Hospital Center Touhami Benflis Algeria   (Algeria)

^d CATHOLIC UNIVERSITY   (Italy)

Author keywords

Alcoholic liver disease; Baclofen; Glucocorticoids; Maddrey's discriminant function; Orthotopic liver transplantation; Severe alcoholic hepatitis

Indexed keywords

BACLOFEN; CORTICOSTEROID; CXCL1 CHEMOKINE; INTERLEUKIN 7; INTERLEUKIN 8; METADOXINE; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITOR; S ADENOSYLMETHIONINE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; DRUGS USED IN THE TREATMENT OF ADDICTION; GLUCOCORTICOID;

ALCOHOL CONSUMPTION; ALCOHOL LIVER DISEASE; ARTICLE; DIET THERAPY; DISEASE COURSE; HISTOLOGY; HISTOPATHOLOGY; HUMAN; INTERNATIONAL NORMALIZED RATIO; LIVER TRANSPLANTATION; MORTALITY; NEUTROPHIL CHEMOTAXIS; PROGNOSIS; SCORING SYSTEM; ACUTE DISEASE; ALCOHOL ABSTINENCE; ANTAGONISTS AND INHIBITORS; DIET SUPPLEMENTATION; HEPATITIS, ALCOHOLIC; IMMUNOLOGY; RISK FACTOR; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ACUTE DISEASE; ALCOHOL ABSTINENCE; ALCOHOL DETERRENTS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; DIETARY SUPPLEMENTS; GLUCOCORTICOIDS; HEPATITIS, ALCOHOLIC; HUMANS; LIVER TRANSPLANTATION; PHOSPHODIESTERASE INHIBITORS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84895871403     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i9.2159     Document Type: Article

References (77)

1. Rehm J, Mathers C, Popova S, Thavorncharoensap M, Teerawattananon Y, Patra J. Global burden of disease and injury and economic cost attributable to alcohol use and alcoholuse disorders. Lancet 2009; 373: 2223-2233 [PMID: 19560604 DOI: 10.1016/S0140-6736(09)60746-7]
2. Maddrey WC. Alcoholic hepatitis: clinicopathologic features and therapy. Semin Liver Dis 1988; 8: 91-102 [PMID: 2834829 DOI: 10.1055/s-2008-1040531]
3. Beckett AG, Livingstone AV, HILL KR. Acute alcoholic hepatitis. Br Med J 1961; 2: 1113-1119 [PMID: 13866411]
4. Zakhari S, Li TK. Determinants of alcohol use and abuse: Impact of quantity and frequency patterns on liver disease. Hepatology 2007; 46: 2032-2039 [PMID: 18046720 DOI: 10.1002/hep.22010]
5. Naveau S, Giraud V, Borotto E, Aubert A, Capron F, Chaput JC. Excess weight risk factor for alcoholic liver disease. Hepatology 1997; 25: 108-111 [PMID: 8985274]
6. Eagon PK. Alcoholic liver injury: influence of gender and hormones. World J Gastroenterol 2010; 16: 1377-1384 [PMID: 20238405 DOI: 10.3748/wjg.v16.i11.1377]
7. Wiley TE, McCarthy M, Breidi L, McCarthy M, Layden TJ. Impact of alcohol on the histological and clinical progression of hepatitis C infection. Hepatology 1998; 28: 805-809 [PMID: 9731576]
8. Machado MV, Ravasco P, Martins A, Almeida MR, Camilo ME, Cortez-Pinto H. Iron homeostasis and H63D mutations in alcoholics with and without liver disease. World J Gastroenterol 2009; 15: 106-111 [PMID: 19115475 DOI: 10.3748/ wjg.15.106]
9. Schwartz JM, Reinus JF. Prevalence and natural history of alcoholic liver disease. Clin Liver Dis 2012; 16: 659-666 [PMID: 23101975 DOI: 10.1016/j.cld.2012.08.001]
10. Addolorato G, Capristo E, Greco AV, Caputo F, Stefanini GF, Gasbarrini G. Three months of abstinence from alcohol normalizes energy expenditure and substrate oxidation in alcoholics: a longitudinal study. Am J Gastroenterol 1998; 93: 2476-2481 [PMID: 9860412 DOI: 10.1111/j.1572-0241.1998.00707.x]
11. Paulson QX, Hong J, Holcomb VB, Nunez NP. Effects of body weight and alcohol consumption on insulin sensitivity. Nutr J 2010; 9: 14 [PMID: 20307313 DOI: 10.1186/1475-2891-9-14]
12. Loria P, Marchesini G, Nascimbeni F, Ballestri S. Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology. Atherosclerosis 2014; 23: 99-109 [DOI: 10.1016/j.atherosclerosis.2013.10.030]
13. Balbão CE, de Paola AA, Fenelon G. Effects of alcohol on atrial fibrillation: myths and truths. Ther Adv Cardiovasc Dis 2009; 3: 53-63 [PMID: 19124390 DOI: 10.1177/1753944708096 380]
14. Boé DM, Vandivier RW, Burnham EL, Moss M. Alcohol abuse and pulmonary disease. J Leukoc Biol 2009; 86: 1097-1104 [PMID: 19602670 DOI: 10.1189/jlb.0209087]
15. Vonghia L, Leggio L, Ferrulli A, Bertini M, Gasbarrini G, Addolorato G. Acute alcohol intoxication. Eur J Intern Med 2008; 19: 561-567 [PMID: 19046719 DOI: 10.1016/j.ejim.2007.06.033]
16. Addolorato G, Capristo E, Gasbarrini G, Stefanini GF. Depression, alcohol abuse and orocaecal transit time. Gut 1997; 41: 417-418 [PMID: 9378406]
17. Bardou M, Montembault S, Giraud V, Balian A, Borotto E, Houdayer C, Capron F, Chaput JC, Naveau S. Excessive alcohol consumption favours high risk polyp or colorectal cancer occurrence among patients with adenomas: a case control study. Gut 2002; 50: 38-42 [PMID: 11772965 DOI: 10.1136/gut.50.1.38]
18. Sohail U, Satapathy SK. Diagnosis and management of alcoholic hepatitis. Clin Liver Dis 2012; 16: 717-736 [PMID: 23101979 DOI: 10.1016/j.cld.2012.08.005]
19. Fleming RL, Manis PB, Morrow AL. The effects of acute and chronic ethanol exposure on presynaptic and postsynaptic gamma-aminobutyric acid (GABA) neurotransmission in cultured cortical and hippocampal neurons. Alcohol 2009; 43: 603-618 [PMID: 20004338 DOI: 10.1016/j.alcohol.2009.10.006]
20. Basra G, Basra S, Parupudi S. Symptoms and signs of acute alcoholic hepatitis. World J Hepatol 2011; 3: 118-120 [PMID: 21731904 DOI: 10.4254/wjh.v3.i5.118]
21. Gao B, Bataller R. Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology 2011; 141: 1572-1585 [PMID: 21920463 DOI: 10.1053/j.gastro.2011.09.002]
22. Orman ES, Odena G, Bataller R. Alcoholic liver disease: pathogenesis, management, and novel targets for therapy. J Gastroenterol Hepatol 2013; 28 Suppl 1: 77-84 [PMID: 23855300 DOI: 10.1111/jgh.12030]
23. Voican CS, Perlemuter G, Naveau S. Mechanisms of the inflammatory reaction implicated in alcoholic hepatitis: 2011 update. Clin Res Hepatol Gastroenterol 2011; 35: 465-474 [PMID: 21571602 DOI: 10.1016/j.clinre.2011.01.017]
24. Jüngst C, Berg T, Cheng J, Green RM, Jia J, Mason AL, Lammert F. Intrahepatic cholestasis in common chronic liver diseases. Eur J Clin Invest 2013; 43: 1069-1083 [PMID: 23927644 DOI: 10.1111/eci.12128]
25. Lucey MR, Mathurin P, Morgan TR. Alcoholic hepatitis. N Engl J Med 2009; 360: 2758-2769 [PMID: 19553649 DOI: 10.1056/NEJMra0805786]
26. O'Shea RS, Dasarathy S, McCullough AJ. Alcoholic liver disease. Hepatology 2010; 51: 307-328 [PMID: 20034030 DOI: 10.1002/hep.23258]
27. Tannapfel A, Denk H, Dienes HP, Langner C, Schirmacher P, Trauner M, Flott-Rahmel B. Histopathological diagnosis of non-alcoholic and alcoholic fatty liver disease. Virchows Arch 2011; 458: 511-523 [PMID: 21442288 DOI: 10.1007/ s00428-011-1066-1]
28. Potts JR, Verma S. Alcoholic hepatitis: diagnosis and management in 2012. Expert Rev Gastroenterol Hepatol 2012; 6: 695-710 [PMID: 23237255 DOI: 10.1586/egh.12.57]
29. Lefkowitch JH. Morphology of alcoholic liver disease. Clin Liver Dis 2005; 9: 37-53 [PMID: 15763228 DOI: 10.1016/ j.cld.2004.11.001]
30. Mookerjee RP, Lackner C, Stauber R, Stadlbauer V, Deheragoda M, Aigelsreiter A, Jalan R. The role of liver biopsy in the diagnosis and prognosis of patients with acute deterioration of alcoholic cirrhosis. J Hepatol 2011; 55: 1103-1111 [PMID: 21376092 DOI: 10.1016/j.jhep.2011.02.021]
31. Maddrey WC, Boitnott JK, Bedine MS, Weber FL, Mezey E, White RI. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology 1978; 75: 193-199 [PMID: 352788]
32. Dunn W, Jamil LH, Brown LS, Wiesner RH, Kim WR, Menon KV, Malinchoc M, Kamath PS, Shah V. MELD accurately predicts mortality in patients with alcoholic hepatitis. Hepatology 2005; 41: 353-358 [PMID: 15660383 DOI: 10.1002/ hep.20503]
33. Forrest EH, Morris AJ, Stewart S, Phillips M, Oo YH, Fisher NC, Haydon G, O'Grady J, Day CP. The Glasgow alcoholic hepatitis score identifies patients who may benefit from corticosteroids. Gut 2007; 56: 1743-1746 [PMID: 17627961 DOI: 10.1136/gut.2006.099226]
34. Dominguez M, Rincón D, Abraldes JG, Miquel R, Colmenero J, Bellot P, García-Pagán JC, Fernández R, Moreno M, Bañares R, Arroyo V, Caballería J, Ginès P, Bataller R. A new scoring system for prognostic stratification of patients with alcoholic hepatitis. Am J Gastroenterol 2008; 103: 2747-2756 [PMID: 18721242 DOI: 10.1111/j.1572-0241.2008.02104.x]
35. Louvet A, Naveau S, Abdelnour M, Ramond MJ, Diaz E, Fartoux L, Dharancy S, Texier F, Hollebecque A, Serfaty L, Boleslawski E, Deltenre P, Canva V, Pruvot FR, Mathurin P. The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. Hepatology 2007; 45: 1348-1354 [PMID: 17518367 DOI: 10.1002/hep.21607]
36. Amini M, Runyon BA. Alcoholic hepatitis 2010: a clinician's guide to diagnosis and therapy. World J Gastroenterol 2010; 16: 4905-4912 [PMID: 20954276 DOI: 10.3748/wjg.v16. i39.4905]
37. Choi G, Runyon BA. Alcoholic hepatitis: a clinician's guide. Clin Liver Dis 2012; 16: 371-385 [PMID: 22541704 DOI: 10.1016/j.cld.2012.03.015]
38. Imperiale TF, McCullough AJ. Do corticosteroids reduce mortality from alcoholic hepatitis? A meta-analysis of the randomized trials. Ann Intern Med 1990; 113: 299-307 [PMID: 2142869 DOI: 10.7326/0003-4819-113-4-299]
39. Christensen E, Gluud C. Glucocorticoids are ineffective in alcoholic hepatitis: a meta-analysis adjusting for confounding variables. Gut 1995; 37: 113-118 [PMID: 7672658 DOI: 10.1136/gut.37.1.113]
40. Rambaldi A, Saconato HH, Christensen E, Thorlund K, Wetterslev J, Gluud C. Systematic review: glucocorticosteroids for alcoholic hepatitis--a Cochrane Hepato-Biliary Group systematic review with meta-analyses and trial sequential analyses of randomized clinical trials. Aliment Pharmacol Ther 2008; 27: 1167-1178 [PMID: 18363896 DOI: 10.1111/ j.1365-2036.2008.03685.x]
41. Mathurin P, O'Grady J, Carithers RL, Phillips M, Louvet A, Mendenhall CL, Ramond MJ, Naveau S, Maddrey WC, Morgan TR. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data. Gut 2011; 60: 255-260 [PMID: 20940288 DOI: 10.1136/gut.2010.224097]
42. European Association for the Study of Liver. EASL clinical practical guidelines: management of alcoholic liver disease. J Hepatol 2012; 57: 399-420 [PMID: 22633836 DOI: 10.1016/ j.jhep.2012.04.004]
43. Whitfield K, Rambaldi A, Wetterslev J, Gluud C. Pentoxifylline for alcoholic hepatitis. Cochrane Database Syst Rev 2009; (4): CD007339 [PMID: 19821406 DOI: 10.1002/14651858. CD007339.pub2]
44. Sidhu SS, Goyal O, Singla P, Gupta D, Sood A, Chhina RS, Soni RK. Corticosteroid plus pentoxifylline is not better than corticosteroid alone for improving survival in severe alcoholic hepatitis (COPE trial). Dig Dis Sci 2012; 57: 1664-1671 [PMID: 22388710 DOI: 10.1007/s10620-012-2097-4]
45. Mathurin P, Louvet A, Duhamel A, Nahon P, Carbonell N, Boursier J, Anty R, Diaz E, Thabut D, Moirand R, Lebrec D, Moreno C, Talbodec N, Paupard T, Naveau S, Silvain C, Pageaux GP, Sobesky R, Canva-Delcambre V, Dharancy S, Salleron J, Dao T. Prednisolone with vs without pentoxifylline and survival of patients with severe alcoholic hepatitis: a randomized clinical trial. JAMA 2013; 310: 1033-1041 [PMID: 24026598 DOI: 10.1001/jama.2013.276300]
46. Lebrec D, Thabut D, Oberti F, Perarnau JM, Condat B, Barraud H, Saliba F, Carbonell N, Renard P, Ramond MJ, Moreau R, Poynard T. Pentoxifylline does not decrease shortterm mortality but does reduce complications in patients with advanced cirrhosis. Gastroenterology 2010; 138: 1755-1762 [PMID: 20102716 DOI: 10.1053/j.gastro.2010.01.040]
47. Parker R, Armstrong MJ, Corbett C, Rowe IA, Houlihan DD. Systematic review: pentoxifylline for the treatment of severe alcoholic hepatitis. Aliment Pharmacol Ther 2013; 37: 845-854 [PMID: 23489011 DOI: 10.1111/apt.12279]
48. Mookerjee RP, Sen S, Davies NA, Hodges SJ, Williams R, Jalan R. Tumour necrosis factor alpha is an important mediator of portal and systemic haemodynamic derangements in alcoholic hepatitis. Gut 2003; 52: 1182-1187 [PMID: 12865279 DOI: 10.1136/gut.52.8.1182]
49. Vojtěchovský M, Král J. Proceedings: Chlorprothixen and thioridazine in maintenance therapy of longterm hospital psychotics. Act Nerv Super (Praha) 1975; 17: 212-213 [PMID: 1221759 DOI: 10.1016/S0168-8278(02)00230-1]
50. Naveau S, Chollet-Martin S, Dharancy S, Mathurin P, Jouet P, Piquet MA, Davion T, Oberti F, Broët P, Emilie D. A doubleblind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology 2004; 39: 1390-1397 [PMID: 15122768 DOI: 10.1002/ hep.20206]
51. Boetticher NC, Peine CJ, Kwo P, Abrams GA, Patel T, Aqel B, Boardman L, Gores GJ, Harmsen WS, McClain CJ, Kamath PS, Shah VH. A randomized, double-blinded, placebocontrolled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology 2008; 135: 1953-1960 [PMID: 18848937 DOI: 10.1053/j.gastro.2008.08.057]
52. Addolorato G, Ancona C, Capristo E, Gasbarrini G. Metadoxine in the treatment of acute and chronic alcoholism: a review. Int J Immunopathol Pharmacol 2003; 16: 207-214 [PMID: 14611722]
53. Leggio L, Kenna GA, Ferrulli A, Zywiak WH, Caputo F, Swift RM, Addolorato G. Preliminary findings on the use of metadoxine for the treatment of alcohol dependence and alcoholic liver disease. Hum Psychopharmacol 2011; 26: 554-559 [PMID: 22095793 DOI: 10.1002/hup.1244]
54. Caballería J, Parés A, Brú C, Mercader J, García Plaza A, Caballería L, Clemente G, Rodrigo L, Rodés J. Metadoxine accelerates fatty liver recovery in alcoholic patients: results of a randomized double-blind, placebo-control trial. Spanish Group for the Study of Alcoholic Fatty Liver. J Hepatol 1998; 28: 54-60 [PMID: 9537864]
55. Medici V, Virata MC, Peerson JM, Stabler SP, French SW, Gregory JF, Albanese A, Bowlus CL, Devaraj S, Panacek EA, Richards JR, Halsted CH. S-adenosyl-L-methionine treatment for alcoholic liver disease: a double-blinded, randomized, placebo-controlled trial. Alcohol Clin Exp Res 2011; 35: 1960-1965 [PMID: 22044287 DOI: 10.1111/j.1530-0277.2011.01547.x]
56. Mato JM, Cámara J, Fernández de Paz J, Caballería L, Coll S, Caballero A, García-Buey L, Beltrán J, Benita V, Caballería J, Solà R, Moreno-Otero R, Barrao F, Martín-Duce A, Correa JA, Parés A, Barrao E, García-Magaz I, Puerta JL, Moreno J, Boissard G, Ortiz P, Rodés J. S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. J Hepatol 1999; 30: 1081-1089 [PMID: 10406187]
57. Abenavoli L, Capasso R, Milic N, Capasso F. Milk thistle in liver diseases: past, present, future. Phytother Res 2010; 24: 1423-1432 [PMID: 20564545 DOI: 10.1002/ptr.3207]
58. Song Z, Deaciuc I, Song M, Lee DY, Liu Y, Ji X, McClain C. Silymarin protects against acute ethanol-induced hepatotoxicity in mice. Alcohol Clin Exp Res 2006; 30: 407-413 [PMID: 16499481 DOI: 10.1111/j.1530-0277.2006.00063.x]
59. Singal AK, Charlton MR. Nutrition in alcoholic liver disease. Clin Liver Dis 2012; 16: 805-826 [PMID: 23101983 DOI: 10.1016/j.cld.2012.08.009]
60. McClain CJ, Barve SS, Barve A, Marsano L. Alcoholic liver disease and malnutrition. Alcohol Clin Exp Res 2011; 35: 815-820 [PMID: 21284673 DOI: 10.1111/j.1530-0277.2010.01405.x]
61. Cabré E, Rodríguez-Iglesias P, Caballería J, Quer JC, Sánchez-Lombraña JL, Parés A, Papo M, Planas R, Gassull MA. Short-and long-term outcome of severe alcohol-induced hepatitis treated with steroids or enteral nutrition: a multicenter randomized trial. Hepatology 2000; 32: 36-42 [PMID: 10869286 DOI: 10.1053/jhep.2000.8627]
62. Alvarez MA, Cabré E, Lorenzo-Zúñiga V, Montoliu S, Planas R, Gassull MA. Combining steroids with enteral nutrition: a better therapeutic strategy for severe alcoholic hepatitis? Results of a pilot study. Eur J Gastroenterol Hepatol 2004; 16: 1375-1380 [PMID: 15618848]
63. Elisaf M, Liberopoulos E, Bairaktari E, Siamopoulos K. Hypokalaemia in alcoholic patients. Drug Alcohol Rev 2002; 21: 73-76 [PMID: 12189007]
64. Rees E, Gowing LR. Supplementary thiamine is still important in alcohol dependence. Alcohol Alcohol 2013; 48: 88-92 [PMID: 23161892 DOI: 10.1093/alcalc/ags120]
65. Addolorato G, Mirijello A, Leggio L, Ferrulli A, Landolfi R. Management of alcohol dependence in patients with liver disease. CNS Drugs 2013; 27: 287-299 [PMID: 23456576 DOI: 10.1007/s40263-013-0043-4]
66. Kershenobich D, Corona DL, Kershenovich R, Gutierrez-Reyes G. Management of alcoholic liver disease: an update. Alcohol Clin Exp Res 2011; 35: 804-805 [PMID: 21284670 DOI: 10.1111/j.1530-0277.2010.01402.x]
67. Colombo G, Agabio R, Carai MA, Lobina C, Pani M, Reali R, Addolorato G, Gessa GL. Ability of baclofen in reducing alcohol intake and withdrawal severity: I--Preclinical evidence. Alcohol Clin Exp Res 2000; 24: 58-66 [PMID: 10656194 DOI: 10.1111/j.1530-0277.2000.tb04554.x]
68. Addolorato G, Leggio L, Abenavoli L, Agabio R, Caputo F, Capristo E, Colombo G, Gessa GL, Gasbarrini G. Baclofen in the treatment of alcohol withdrawal syndrome: a comparative study vs diazepam. Am J Med 2006; 119: 276. e13-276. e18 [PMID: 16490478 DOI: 10.1016/j.amjmed.2005.08.042]
69. Addolorato G, Leggio L, Ferrulli A, Cardone S, Bedogni G, Caputo F, Gasbarrini G, Landolfi R. Dose-response effect of baclofen in reducing daily alcohol intake in alcohol dependence: secondary analysis of a randomized, double-blind, placebo-controlled trial. Alcohol Alcohol 2011; 46: 312-317 [PMID: 21414953 DOI: 10.1093/alcalc/agr017]
70. Addolorato G, Leggio L, Ferrulli A, Cardone S, Vonghia L, Mirijello A, Abenavoli L, D'Angelo C, Caputo F, Zambon A, Haber PS, Gasbarrini G. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet 2007; 370: 1915-1922 [PMID: 18068515 DOI: 10.1016/S0140-6736(07)61814-5]
71. Avanesyan A, Runyon BA. Utilization of baclofen in maintenance of alcohol abstinence in patients with alcoholic hepatitis in a real life clinical setting. Hepatology 2010; 52: 1104A
72. Dureja P, Lucey MR. The place of liver transplantation in the treatment of severe alcoholic hepatitis. J Hepatol 2010; 52: 759-764 [PMID: 20347501 DOI: 10.1016/j.jhep.2009.12.021]
73. Burra P, Senzolo M, Adam R, Delvart V, Karam V, Germani G, Neuberger J. Liver transplantation for alcoholic liver disease in Europe: a study from the ELTR (European Liver Transplant Registry). Am J Transplant 2010; 10: 138-148 [PMID: 19951276 DOI: 10.1111/j.1600-6143.2009.02869.x]
74. Mathurin P, Moreno C, Samuel D, Dumortier J, Salleron J, Durand F, Castel H, Duhamel A, Pageaux GP, Leroy V, Dharancy S, Louvet A, Boleslawski E, Lucidi V, Gustot T, Francoz C, Letoublon C, Castaing D, Belghiti J, Donckier V, Pruvot FR, Duclos-Vallée JC. Early liver transplantation for severe alcoholic hepatitis. N Engl J Med 2011; 365: 1790-1800 [PMID: 22070476 DOI: 10.1056/NEJMoa1105703]
75. Addolorato G, Mirijello A, Leggio L, Ferrulli A, D'Angelo C, Vassallo G, Cossari A, Gasbarrini G, Landolfi R, Agnes S, Gasbarrini A. Liver transplantation in alcoholic patients: impact of an alcohol addiction unit within a liver transplant center. Alcohol Clin Exp Res 2013; 37: 1601-1608 [PMID: 23578009 DOI: 10.1111/acer.12117]
76. Breitkopf K, Nagy LE, Beier JI, Mueller S, Weng H, Dooley S. Current experimental perspectives on the clinical progression of alcoholic liver disease. Alcohol Clin Exp Res 2009; 33: 1647-1655 [PMID: 19645734 DOI: 10.1111/j.1530-0277.2009.01015.x]
77. Brandon-Warner E, Schrum LW, Schmidt CM, McKillop IH. Rodent models of alcoholic liver disease: of mice and men. Alcohol 2012; 46: 715-725 [PMID: 22960051 DOI: 10.1016/ j.alcohol.2012.08.004]